About the API
Dasatinib monohydrate is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
Dasatinib was approved by the FDA in 2006 under the trade name Sprycel, for use as a second-line drug. It was approved in 2010 for use in newly diagnosed adults in the chronic phase. Dasatinib is synthesized through a chemical process involving carbon-nitrogen bond formation as major step.